Epilepsy remains a major area of focus and commitment for our internal development program at PORSOLT.
We recently validated two novel reference compounds in our Electrical Amygdala Kindling in vivo model: Retigabine and Perampanel (third generation drug), in keeping up with the most recent clinical developments and the…
Continue Reading
Epilepsy remains a major area of focus and commitment for our internal development program at PORSOLT.